Creative Bioarray Included Its Primary Cells Products Into Featured Products Line

Creative Bioarray added primary cells into its key products line and announced the news officially on 2nd, August. This is a further step that the company took to become a more comprehensive cells supplier.

Under the category of primary cells, Creative Bioarray provides human primary cells, rat primary cells, mouse primary cells and primary cells from 11 other species. With increase of the related studies, primary cells are more frequently requested and inquired by clients, thus the company set to optimize the products in this aspect and try to provide a wider scope of cells types to meet various research needs. Besides, primary cells are also quite often employed to replace animal tests in aspects that in vivo cells culture and observation can help to achieve.

Of note, with the development of 3D cell culture system, primary cells will be more widely applied in cells related researches and studies. Thus it’s quite necessary for cells supplier like Creative Bioarray to prepare the involved cells well. Then the action for Creative Bioarray will be definitely a right decision for the company in future general development.

For human primary cells that are commonly involved in various disease studies and treatment development, 35 systems including over 160 types of cells are available at Creative Bioarray. In addition to being featured, the primary cells will be optimized in their variety and quality to ensure research result, and the optimization will be taken place within this year.

Other species for animal primary cells that are accessible here contains rabbit, monkey, pig, dog, chicken, horse, mink, bovine, hamster and so on.

About author

Creative Bioarray masters in providing cells and cells related kits and reagents. With about 11 years experience in the field, the company is capable of providing cells product with high quality in an effective manner. Besides with primary cells, tumor cells and stem cells are also supplied. For more information please visit the website.

Back to news